GIANT BIOGENE

Giant Biogene closed at HKD 30.62 today with a 1.23% decline, as morning weakness gradually stabilized during afternoon trading. The retreat reflects headwinds from recent financial results and sector rotation. Q4 2025 earnings showed revenue of HKD 1.338 billion (down 16% YoY) and net profit of HKD 407 million (down 29% YoY), with EPS declining 34% YoY—profit contraction exceeding revenue decline suggests rising cost pressures. However, the company's recent NMPA approval for a recombinant type III collagen neck filler presents a new growth catalyst, though consumer traction remains to be validated. From a valuation lens, the current P/E of 15.33 and P/B of 2.96 appear modest, yet the stock has declined 53% from its 52-week high of HKD 65.7 (set September 2025) and remains down 10.5% year-to-date, reflecting persistent market skepticism. Institutional views remain divided—CICC set a target price of HKD 40, while multiple houses maintain buy ratings. The broader market backdrop features capital rotating toward higher-yielding assets and advanced manufacturing, creating headwinds for consumer healthcare exposure.

Giant Biogene declined 0.48% to HKD 28.90, pressured by weakening fundamentals and growing analyst divergence. Q4 revenue came in at HKD 1.338 billion, down 16.13% year-over-year, while net profit contracted 29.03% to HKD 407.4 million, reflecting broad-based softness across the income statement. Analyst ratings have fractured, with Jefferies recently adopting Hold versus ongoing Buy ratings from BofA, Huatai, and Orient Securities; CICC had previously cut its target price to HKD 40, signaling softened near-term growth expectations. On the positive side, the company recently obtained regulatory approval for a recombinant type III collagen filler for neck wrinkles, introducing a potential new growth catalyst. The stock has retreated 15.55% year-to-date and trades 56% below its 52-week high, though it continues trading above both the 20-day and 60-day moving averages, providing near-term technical support.

Giant Biogene rose 0.48% to HKD 29.04, with morning strength peaking at HKD 29.70 followed by afternoon weakness, reflecting market caution on company fundamentals. Q4 results show revenue declining 16.13% year-over-year to HKD 1.338 billion, with net profit down 29.03%, while net margins held above 30%, signaling margin compression amid softer demand. Positively, the company secured NMPA approval for a neck-filler product and most brokers maintain Buy ratings; however, Jefferies recently switched to Hold and CICC cut its target price to HKD 40. Price-wise, the stock has fallen 55.8% from its 52-week peak of HKD 65.70 and now sits only 20% above the 52-week trough of HKD 24.20, though down 15.14% year-to-date. Despite reasonable valuations at PE 14.5x and PB 2.81x, investor views remain divided on growth prospects given intensifying competition in the cosmeceutical sector and weakening demand.

Given the recent earnings deterioration, stock 2367.HK retreated by 0.96% to HKD 28.90, as early morning strength gradually eroded into afternoon selling pressure. Revenue slid 16%-21% year-over-year in the latest two quarters, while net profit tumbled 29%-33%, weighing on EPS and investor sentiment. The company did secure NMPA approval for its first recombinant Type III collagen neck filler, a new product that should fuel longer-term growth, but this catalyst has yet to meaningfully lift near-term earnings. Valuation remains reasonable with PE of 14.47 and PB of 2.80; however, the stock has declined 15.55% year-to-date and trades 56% below its 52-week high, suggesting the market has fully priced in concerns over slowing growth. Analyst views are mixed: Jefferies recently downgraded to Hold, while Citi, Goldman Sachs, Huatai and others maintain Buy ratings, with CICC targeting HKD 40 per share as a bottom-fishing opportunity, indicating expectations for an eventual recovery.

Giant Biogene displayed a bifurcated intraday pattern, surging to a morning high of HKD 30.28 before sharp afternoon selling pressure drove the stock down to HKD 29.18, closing down 1.42% on the day. Latest earnings data reveal concerning profitability trends with Q4 2025 EPS declining 34.46% year-over-year and Q3 dropping 38.17%, while revenue fell 16.13% in Q4, signaling persistent earnings headwinds. The company recently secured NMPA approval for its recombinant collagen filler product, yet Jefferies downgraded the rating to Hold and CICC cut its price target to HKD 40, reflecting institutional caution on earnings recovery. From a valuation perspective, the stock has retreated 55.59% from its 52-week high of HKD 65.7 and declined 14.73% year-to-date, while trading at a PE multiple of 14.61x—seemingly attractive but clouded by deteriorating profit trends.